Coeptis Therapeutics (NASDAQ:ZSQR) Sees Strong Trading Volume – Time to Buy?

Shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) saw strong trading volume on Tuesday . 58,682 shares were traded during mid-day trading, a decline of 45% from the previous session’s volume of 107,489 shares.The stock last traded at $13.32 and had previously closed at $12.77.

Analyst Ratings Changes

Separately, Wall Street Zen cut shares of Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Coeptis Therapeutics Trading Up 8.1%

The firm has a market cap of $709.73 million, a P/E ratio of -5.48 and a beta of -0.22. The business’s 50-day moving average is $11.90 and its two-hundred day moving average is $12.90. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.25 and a quick ratio of 3.25.

Coeptis Therapeutics (NASDAQ:ZSQR) last released its earnings results on Thursday, May 14th. The company reported ($0.65) earnings per share for the quarter. The business had revenue of $0.11 million during the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC grew its position in Coeptis Therapeutics by 100.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after purchasing an additional 2,500 shares in the last quarter. Yorkville Advisors Global LP acquired a new stake in Coeptis Therapeutics in the third quarter valued at $140,000. Marshall Wace LLP acquired a new stake in Coeptis Therapeutics in the fourth quarter valued at $259,000. State Street Corp lifted its stake in Coeptis Therapeutics by 35.0% in the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after acquiring an additional 6,962 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Coeptis Therapeutics by 12.6% in the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after acquiring an additional 4,721 shares during the last quarter. Institutional investors own 13.88% of the company’s stock.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.